Published: September 2012


Ondansetron: New Dose Restrictions

Prescriber Update 33(3): 21
September 2012

A new clinical study conducted by the company shows that there is a significant risk of QT prolongation in patients given high doses of ondansetron used to manage nausea and vomiting induced by highly emetogenic chemotherapy.

Consequently, the following changes and advice are recommended.

  • The new maximum intravenous dose for adults is 16mg infused over at least 15 minutes.
  • Ondansetron should be avoided in patients with congenital QT syndrome.
  • Caution should be used if ondansetron is administered to patients with risk factors for QT interval prolongation.
  • Hypokalaemia and hypomagnesaemia should be corrected prior to ondansetron administration.

Ondansetron data sheets are currently being updated.


Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /